ABVX:EPA
Abivax SA
€ 77.15
arrow_downward
-0.64%(-0.50) Siku 1
6 Nov, 17:36:06 GMT +1 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya ABVX...
Fungua
€ 74.45
Juu
€ 77.15
Chini
€ 73.80
Mtaji wa soko
6.84B
Wastani wa kiasi cha mauzo
elfu 111.44
Kiasi cha mauzo ya hisa
elfu 161.37
Juu kwa wiki 52
€ 139.00
Chini kwa wiki 52
€ 60.45
EPS
-€ 5.20
Hisa za wawekezaji
87.55M
Idadi ya wafanyakazi
98
Fungua
€ 74.45
Juu
€ 77.15
Chini
€ 73.80
Mtaji wa soko
6.84B
Wastani wa kiasi cha mauzo
elfu 111.44
Kiasi cha mauzo ya hisa
elfu 161.37
Juu kwa wiki 52
€ 139.00
Chini kwa wiki 52
€ 60.45
EPS
-€ 5.20
Hisa za wawekezaji
87.55M
Idadi ya wafanyakazi
98
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Trefis
·
saa 1 iliyopita
The S&P 500 Is Up 75% In 3 Years. Priced In Gold, It Is Down 14%. Which Is Real?
Fox Business
·
saa 12 zilizopita
Nasdaq rallies as chip stocks recover from brutal losses
Bloomberg.com
·
saa 21 zilizopita
Fast-Money Systematic Funds Stoked $2.3 Trillion Tech-Stock Rout
CNN
·
siku 1 iliyopita
What sparked the stock market’s $2.5 trillion sell-off?
Wasifu
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Kuhusu Abivax SA
Afisa Mkuu Mtendaji (CEO)Marc de Garidel | Hartmut J. Ehrlich
Wafanyakazi98
Lilianzishwa4 Des 2013
Makao makuu-
SektaHealth Care
Sekta-
Tovutiabivax.com